In This Issue
Journal: Cancer Discovery (2022)

In This Issue| August 05 2022 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2022 American Association for Cancer Research.2022American Association for Cancer Research. Cancer Discov (2022) 12 (8): 1825–1826. https://doi.org/10.1158/2159-8290.CD-12-8-ITI Related Content A commentary has been published: Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms A commentary has been published: Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance A commentary has been published: Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma View more A commentary has been published: Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice A commentary has been published: Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer A commentary has been published: BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL A commentary has been published: IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma A commentary has been published: Stress Granules Determine the Development of Obesity-Associated Pancreatic Cancer View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record August 5 2022 Citation In This Issue. Cancer Discov 1 August 2022; 12 (8): 1825–1826. https://doi.org/10.1158/2159-8290.CD-12-8-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Chemotherapy exposure increases the risk for therapy-related cancer; however, the mutational consequences of treatment in healthy cells of cancer survivors remain unknown. Bertrums, Rosendahl Huber, de Kanter, and colleagues studied the mutation burden in hematopoietic stem cells of children treated for cancer, revealing an increased treatment-associated mutation burden comparable to the accumulation observed during 16 years of healthy life. This was mostly caused by clock-like processes that are also active during normal aging. Phylogenetic inference of somatic mutations in single cells indicated that most therapy-related myeloid neoplasms originated after the start of treatment and became dominant during or after chemotherapy exposure. See article, p. 1860. Initiation and progression of colorectal cancer (CRC) can be induced through components of the gut microbiome, with protumorigenic organisms still being defined. Drewes, Chen, Markham, and colleagues tested the tumorigenic potential of colonic mucosal slurries derived from patients with CRC and found that colon... You do not currently have access to this content.